Slide 1: Optomed Q3 2024
Optomed Q3 2024 7th November 2024 Juho Himberg, CEO Sakari Knuutti, CFO
Slide 2: Highlights
Highlights 1. 2. 3. FY 24 revenue Handheld extremely Q3 performance outlook reduced well positioned at declined vs Q3-23 from ‘growth’ Oculomics and that was supported to ‘decline’ Aurora AEYE’s by two one-time commercialization large deliveries is progressing
Slide 3: Q3-2024 Key Figures
Q3-2024 Key Figures OUR TOPLINE DECLINED VS TOUGH COMPARISION PERIOD THAT INCLUDED TWO LARGE DELIVERIES Q3/2024 Q3/2023 Change Revenue 3,109 4,218 -26.3% Gross profit 1,692 2,841 -40.4% Gross margin* 54.4% 67.4% -130pps EBITDA -814 263 -409.5% EBITDA margin -26.2% 6.2% -324pps Net profit / loss -1,5
Slide 4: Q1-Q3/2024 Key Figures
Q1-Q3/2024 Key Figures OUR Q1-Q3 TOPLINE IS DOWN 13.1 % Y-o-Y Q1-Q3/2024 Q1-Q3/2023 Change Revenue 9,941 11,440 -13.1% Gross profit 6,355 7,803 -18.6% Gross margin 63.9% 68.2% -43pps EBITDA -2,264 -713 -217.7% EBITDA margin -22.8% -6.2% -166pps Net profit / loss -4,460 -2,911 -53.2% Earnings per sha
Slide 5: Developments in two key markets
Developments in two key markets STRATEGIC DEVELOPMENTS IN USA AND CHINA • Aurora AEYE’s • Joint venture agreement commercialization is signed with Zhongbao Fund progressing well, with promising market traction. • The business model will be a recurring revenue model, • After the initial trial period,
Slide 6: Segment highlights
Segment highlights OPT@MED
Slide 7: Devices Segment Q3-2024
Devices Segment Q3-2024 TOPLINE DOWN BY EUR 1 MILLION AS DEVICES DID NOT RECEIVE ANY LARGE ORDERS THIS QUARTER Q3/2024 Q3/2023 Change Revenue declined by EUR 1,012 million 1. against strong comparison period that was boosted by large customer orders Revenue 813 1,825 -55.5% from Spain and China Gros
Slide 8: Software Segment Q3-2024
Software Segment Q3-2024 SOFTWARE REVENUE DECLINED SLIGHTLY Q3/2024 Q3/2023 Change Software segment revenue declined 1. slightly against a comparison period that grew almost 20% Revenue 2,297 2,393 -4.0% Gross profit 1,602 1,718 -6.8% 2. A win in the dental imaging sector Gross margin 69.7% 71.8% -2
Slide 9: Cash Flow Q3-2024
Cash Flow Q3-2024 CASH POSITION AT EUR 11 MILLION Q3 2024 Q3 2023 Loss for the financial year -1,577 -439 • Received a payment of EUR Cash flows before change 450 thousand from the Chinese in net working capital -1,115 402 customer which reduced the amount of debt by EUR 340 Change in net working ca
Slide 10: Summary
Summary • No large devices order during the quarter and thus Q3 performance did not meet expectations against the strong comparison period with two major orders • Aurora AEYE’s commercialization is progressing well, with promising market traction. • Our next-generation handheld camera has recently o
Slide 11: Appendix
Appendix OPT@MED
Slide 12: Devices Segment Q1-Q3/2024
Devices Segment Q1-Q3/2024 Q1-Q3/2024 Q1-Q3/2023 Change Revenue 2,776 3,986 -30.4 % Gross profit 1,302 2,356 -44.8 % Gross margin 46.9% 59.1% -122pps EBITDA -1,558 -693 -124.6 % EBITDA margin -56.1% -17.4% -387pps
Slide 13: Software Segment Q1-Q3/2024
Software Segment Q1-Q3/2024 Q1-Q3/2024 Q1-Q3/2023 Change Revenue 7,165 7,454 -3.9% Gross profit 5,044 5,447 -7.4% Gross margin 70.4% 73.1% -27 pps EBITDA 1,468 2,004 -26.8% EBITDA margin 20.5% 26.9% -64pps
Slide 14: Cash Flow Q1-Q3/2024
Cash Flow Q1-Q3/2024 Q1-Q3 2024 Q1-Q3 2023 Loss for the financial year -4,460 -2,911 Cash flows before change in net working capital -2,415 -546 Change in net working capital 471 595 Cash flows before finance items 50 -354 Cash flows from finance items -62 -169 Net cash from operating activities -2,
Slide 15: Balance Sheet
Balance Sheet 30 September 2024 30 September 2023 • Equity ratio of 76.5 (68.9) ASSETS percent Goodwill 4,256 4,256 Development costs 8,212 7,493 Other intangible assets 1,494 1,842 • Total borrowings of EUR Total intangible assets 13,962 13,592 2.6 (4.7) million Total tangible assets 592 747 Total